View More View Less
  • 1 Országos Reumatológiai és Fizioterápiás Intézet, Budapest, Frankel Leó u. 38–40., 1023
Restricted access

Absztrakt:

A nagyérvasculitisek közé sorolt óriássejtes arteritisben és Takayasu-arteritisben közös az érfal patogenetikai eltérése, ez alapján felmerül, hogy nem két külön entitásról, hanem egy betegség két megnyilvánulási formájáról van szó. Kezelésükben továbbra is a glükokortikoidé a vezető szerep, szükség esetén cyclophosphamiddal, azatioprinnal, mycofenolat mofetillel kiegészítve. Tekintettel arra, hogy a betegek jelentős része a konvencionális betegségmódosító szerek mellett is szteroiddependens, egyre több klinikai tapasztalat gyűlik a hosszú távú mellékhatások elkerülése érdekében adott biológiai terápiás szerek hatékonyságáról. A szerzők célja az új terápiás lehetőségek áttekintése. A tumornekrózis-faktor-alfa-gátlókkal jó terápiás eredmények vannak Takayasu-arteritisben, de óriássejtes arteritisben nem bizonyultak kellően hatékonynak, ugyanakkor az interleukin-6-gátlóval mindkét betegségben szignifikáns javulást sikerült elérni. Az abatacept és az ustekinumab is ígéretesnek tűnik a nagyérvasculitisek kezelésében. Orv. Hetil., 2017, 158(1), 5–12.

  • 1

    Jennette, J. C., Falk, R. J., Bacon, P. A., et al.: 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum., 2013, 65(1), 1–11.

  • 2

    Maksimowicz-McKinnon, K., Clark, T. M., Hoffmann, G. S.: Takayasu arteritis and giant cell arteritis: a spectrum within the same disease? Medicine (Baltimore), 2009, 88(4), 221–226.

  • 3

    Polachek, A., Pauzner, R., Levartovsky, D. et al.: The fine line between Takayasu arteritis and giant cell arteritis. Clin. Rheumatol., 2015, 34(4), 721–727.

  • 4

    Firestein, G. S., Budd, R. C., Harris, E. D., et al.: Kelley’s textbook of rheumatology. Eight edition. Elsevier Saunders, Philadelphia, 2009, 1409–1426.

  • 5

    Salvarani, C., Cantini, F., Boiardi, L., et al.: Polymyalgia rheumatica and giant-cell arteritis. N. Engl. J. Med., 2002, 347(4), 261–271.

  • 6

    Mackie, S. L., Taylor, J. C, Haroon-Rashid, L., et al.: Association of HLA-DRB1 amino acid residues with giant cell arteritis: genetic association study, meta-analysis and geo-epidemiological investigation. Arthritis Res. Ther., 2015, 17(1), 195.

  • 7

    Gonzalez-Gay, M. A., Piñeiro, A., Gomez-Gigirey, A., et al.: Influence of traditional risk factors of atherosclerosis in the development of severe ischemic complications in giant cell arteritis. Medicine (Baltimore), 2004, 83(6), 342–347.

  • 8

    Alvarez-Lafuente, R., Fernández-Gutiérrez, B., Jover, J. A., et al.: Human parvovirus B19, varicella zoster virus, and human herpes virus 6 in temporal artery biopsy specimens of patients with giant cell arteritis: Analysis with quantitative real time polymerase chain reaction. Ann. Rheum. Dis., 2005, 64(5), 780–782.

  • 9

    Gilden, D., Nagel, M. A.: Varicella zoster virus triggers the immunopathology of giant cell arteritis. Curr. Opin. Rheumatol., 2016, 28(4), 376–382.

  • 10

    Ma-Krupa, W., Jeon, M. S., Spoerl, S., et al.: Activation of arterial wall dendritic cells and breakdown of self-tolerance in giant cell arteritis. J. Exp. Med., 2004, 199(2), 173–183.

  • 11

    Kaiser, M., Weyand, C. M., Björnsson, J., et al.: Platelet-derived growth factor, intimal hyperplasia, and ischemic complications in giant cell arteritis. Arthritis Rheum., 1998, 41(4), 623–633.

  • 12

    Takayasu, M.: A case with peculiar changes of the central retinal vessels. Acta Soc. Ophtalmol. Jpn, 1908, 12, 554.

  • 13

    Chugh, K. S., Sakhuya, V.: Takayasu’s arteritis as a cause of renovascular hypertension in Asian countries. Am. J. Nephrol., 1992, 12(1–2), 1–8.

  • 14

    Watts, R., Al-Taiar, A., Mooney, J., et al.: The epidemiology of Takayasu arteritis in the UK. Rheumatology (Oxford), 2009, 48(8), 1008–1011.

  • 15

    Numano, F., Isohisa, I., Kishi, U., et al.: Takayasu’s disease in twin sisters. Possible genetic factors. Circulation, 1978, 58(1), 173–177.

  • 16

    Tavora, F., Burke, A.: Review of isolated ascending aortitis: Differential diagnosis, including syphilitic, Takayasu’s and giant cell aortitis. Pathology, 2006, 38(4), 302–308.

  • 17

    Chauhan, S. K., Tripathy, N. K., Nityanand, S.: Antigenic targets and pathogenicity of anti-aortic endothelial cell antibodies in Takayasu arteritis. Arthritis Rheum., 2006, 54(7), 2326–2333.

  • 18

    Park, M. C., Park, Y. B., Young, S. Y., et al.: Anti-endothelial cell antibodies and antiphospholipid antibodies in Takayasu’s arteritis: correlations of their titers and isotype distributions with disease activity. Clin. Exp. Rheumatol., 2006, 24(2 Suppl. 41), S10–S16.

  • 19

    Tripathy, N. K., Sinha, N., Nityanand, S.: Interleukin-8 in Takayasu’s arteritis: plasma levels and relationship with disease activity. Clin. Exp. Rheumatol., 2004, 22(Suppl. 36), S27–S30.

  • 20

    Verma, D. K., Tripathy, N. K., Verma, N. S., et al.: Interleukin-12 in Takayasu’s arteritis: plasma concentrations and relationship with disease activity. J. Rheumatol., 2005, 32(12), 2361–2363.

  • 21

    Park, M. C., Lee, S. W., Park, Y. B., et al.: Serum cytokine profiles and their correlations with disease activity in Takayasu’s arteritis. Rheumatology (Oxford), 2006, 45(5), 545–548.

  • 22

    Tripathy, N. K., Chandran, V., Garg, N. K., et al.: Soluble endothelial cell adhesion molecules and their relationship to disease activity in Takayasu’s arteritis. J. Rheumatol., 2008, 35(9), 1842–1845.

  • 23

    Tripathy, N. K., Gupta, P. C., Nityanand, S.: High TNF-α and low IL-2 producing T cells characterize active disease in Takayasu’s arteritis. Clin. Immunol., 2006, 118(2–3), 154–158.

  • 24

    Proven, A., Gabriel, S. E., Orces, C., et al.: Glucocorticoid therapy in giant cell arteritis: duration and adverse outcomes. Arthritis Rheum., 2003, 49(5), 703–708.

  • 25

    Köttler, I., Henes, J. C., Wagner, A. D., et al.: Does glucocorticosteroid-resistant large-vessel vasculitis (giant cell arteritis) exist and how can remission be achieved? A critical review of the literature. Clin. Exp. Rheumatol., 2012, 30(1 Suppl. 70), S114–S129.

  • 26

    Nuenninghoff, D. M., Matteson, E. L.: The role of disease-modifying antirheumatic drugs in the treatment of giant cell arteritis. Clin. Exp. Rheumatol., 2003, 21(6 Suppl. 32), S29–S34.

  • 27

    Hoffman, G. S., Cid, M. C., Hellmann, D. B., et al.: A multicenter, randomized, double-blind, placebo-controlled trial of adjuvant methotrexate treatment for giant cell arteritis. Arthritis Rheum., 2002, 46(5), 1309–1318.

  • 28

    Smith, R., Kuet, K. P., Akil, M., et al.: Is mycophenolate mofetil effective in the treatment of large vessel vasculitis? Rheumatology, 2015, 54(Suppl. 1), i194.

  • 29

    De Silva, M., Hazelman, B. L.: Azathioprine in giant cell arteritis/polymyalgia rheumatica: a double-blind study. Ann. Rheum. Dis., 1986, 45(2), 136–138.

  • 30

    De Boysson, H., Boutemy, J., Creveuil, C., et al.: Is there a place for cyclophosphamide in the treatment of giant-cell arteritis? A case series and systematic review. Semin. Arthritis Rheum., 2013, 43(1), 105–112.

  • 31

    Koster, M. J., Matteson, E. L., Warrington, K. J.: Recent advances in the clinical management of giant cell arteritis and Takayasu arteritis. Curr. Opin. Rheumatol., 2016, 28(3), 211–217.

  • 32

    Ferfar, Y., Mirault, T., Desbois, A. C., et al.: Biotherapies in large vessel vasculitis. Autoimmun. Rev., 2016, 15(6), 544–551.

  • 33

    Hernández-Rodríguez, J., Segarra, M., Vilardell, C., et al.: Tissue production of proinflammatory cytokines (IL-1 β, TNF-α and IL-6) correlates with the intensity of the systemic inflammatory response and with corticosteroid requirements in giant-cell arteritis. Rheumatology (Oxford), 2004, 43(3), 294–301.

  • 34

    Samson, M., Audia, S., Janikashvili, N., et al.: Is TNF-α really involved in giant cell arteritis pathogenesis? Ann. Rheum. Dis. 2014, 73(1), e1.

    • Crossref
    • Export Citation
  • 35

    Martínez-Taboada, V. M., Rodríguez-Valverde, C., Carreño, L., et al.: A double-blind placebo controlled trial of etanercept in patients with giant cell arteritis and corticosteroid side effects. Ann. Rheum. Dis., 2008, 67(5), 625–630.

  • 36

    Hoffman, G. S., Cid, M. C., Rendt-Zagar, K. E., et al.: Infliximab for maintenance of glucocorticosteroid-induced remission of giant cell arteritis: a randomized trial. Ann. Intern. Med., 2007, 146(9), 621–630.

  • 37

    Seror, R., Baron, G., Hachulla, E., et al.: Adalimumab for steroid sparing in patients with giant-cell arteritis: results of a multicentre randomised controlled trial. Ann. Rheum. Dis., 2014, 73(12), 2074–2081.

  • 38

    Weyand, C. M., Fulbright, J. W., Hunder, G. G., et al.: Treatment of giant cell arteritis: interleukin-6 as a biologic marker of disease activity. Arthritis Rheum., 2000, 43(5), 1041–1048.

  • 39

    Lurati, A., Bertani, L., Re, K. A., et al.: Successful treatment of a patient with giant cell vasculitis (Horton arteritis) with tocilizumab a humanized anti-interleukin-6 receptor antibody. Case Rep. Rheumatol., 2012, 2012, Article ID 639612.

  • 40

    Loricera, J., Blanco, R., Castañeda, S., et al.: Tocilizumab in refractory aortitis: study on 16 patients and literature review. Clin. Exp. Rheumatol., 2014, 32(3 Suppl. 82), S79–S89.

  • 41

    Işik, M., Kiliç, L., Doğan, I., et al.: Tocilizumab for giant cell arteritis: an amazing result. Rheumatol. Int., 2013, 33(11), 2961–2962.

  • 42

    Salvarani, C., Magnani, L., Catanoso, M., et al.: Tocilizumab: a novel therapy for patients with large-vessel vasculitis. Rheumatology (Oxford), 2012, 51(1), 151–156.

  • 43

    Unizony, S., Arias-Urdaneta, L., Miloslavsky, E., et al.: Tocilizumab for the treatment of large-vessel vasculitis (giant cell arteritis, Takayasu arteritis) and polymyalgia rheumatica. Arthritis Care Res. (Hoboken), 2012, 64(11), 1720–1729.

  • 44

    Beyer, C., Axmann, R., Sahinbegovic, E., et al.: Anti-interleukin 6 receptor therapy as rescue treatment for giant cell arteritis. Ann. Rheum. Dis., 2011, 70(10), 1874–1875.

  • 45

    Sciascia, S., Rossi, D., Roccatello, D.: Interleukin 6 blockade as steroid-sparing treatment for 2 patients with giant cell arteritis. J. Rheumatol., 2011, 38(9), 2080–2081.

  • 46

    Pazzola, G., Padovano, I., Boiardi, L., et al.: Tocilizumab in glucocorticoid-naïve large-vessel vasculitis. Clin. Exp. Rheumatol., 2013, 31(1 Suppl. 75), S59–S61.

  • 47

    Seitz, M., Reichenbach, S., Bonel, H. M., et al.: Rapid induction of remission in large vessel vasculitis by IL-6 blockade: a case series. Swiss Med. Wkly, 2011, 141, w13156.

  • 48

    Loricera, J., Blanco, R., Hernandez, J. L., et al.: Tocilizumab in giant cell arteritis: Multicenter open-label study of 22 patients. Semin. Arthritis Rheum., 2015, 44(6), 717–723.

  • 49

    Adler, S., Reichenbach, S., Kuchen, S., et al.: Tocilizumab for the treatment of giant cell arteritis: a randomized placebo-controlled trial. Arthritis Rheumatol., 2015, 67(Suppl. 10), 912562.

  • 50

    Villiger, P. M., Adler, S., Kuchen, S., et al.: Tocilizumab for induction and maintenance of remission in giant cell arteritis: a phase 2, randomised, double-blind, placebo-controlled trial. Lancet, 2016, 387(10031), 1921–1927.

  • 51

    Tuckwell, K., Collinson, N., Klearman, M., et al.: Baseline data on patients enrolled in a randomized, double-blind trial of tocilizumab in giant cell arteritis. Arthritis Rheumatol. 2015, 67(Suppl, 10), 2352.

  • 52

    Deng, J., Younge, B. R., Olshen, R. A., et al.: Th17 and Th1 T-cell responses in giant cell arteritis. Circulation, 2010, 121(7), 906–915.

  • 53

    Langford, C., Cuthbertson, D., Ytterberg, S. R., et al.: A randomized double-blind trial of abatacept and glucocorticoids for the treatment of giant cell arteritis. Arthritis Rheumatol., 2015, 67(Suppl. 10).

  • 54

    Conway, R., O’Neill, L., O’Flynn, E., et al.: Ustekinumab for the treatment of refractory giant cell arteritis. Ann. Rheum. Dis., 2016, 75(8), 1578–1569.

  • 55

    Van der Geest, K. S., Abdulahad, W. H., Chalan, P., et al.: Disturbed B cell homeostasis in newly diagnosed giant cell arteritis and polymyalgia rheumatica. Arthritis Rheumatol., 2014, 66(7), 1927–1938.

  • 56

    Hoyer, B. F., Mumtaz, I. M., Loddenkemper, K., et al.: Takayasu arteritis is characterised by disturbances of B cell homeostasis and responds to B cell depletion therapy with rituximab. Ann. Rheum. Dis., 2012, 71(1), 75–79.

  • 57

    Mayrbaeurl, B., Hinterreiter, M., Burgstaller, S., et al.: The first case of a patient with neutropenia and giant-cell arteritis treated with rituximab. Clin. Rheumatol., 2007, 26(9), 1597–1598.

  • 58

    Bhatia, A., Ell, P. J., Edwards J. C.: Anti-CD20 monoclonal antibody (rituximab) as an adjunct in the treatment of giant cell arteritis. Ann. Rheum. Dis., 2005, 64(7), 1099–1100.

  • 59

    Valsakumar, A. K., Valappil, U. C., Jorapur, V., et al.: Role of immunsupressive therapy on clinical, immunological and angiographic outcome in active Takayasu’s arteritis. J. Rheumatol., 2003, 30(8), 1793–1798.

  • 60

    Hoffman, G. S., Merkel, P. A., Brasington, R. D., et al.: Anti-tumor necrosis factor therapy in patients with difficult to treat Takayasu arteritis. Arthritis Rheum., 2004, 50(7), 2296–2304.

  • 61

    Molloy, E. S., Langford, C. A., Clark, T. M., et al.: Anti-tumor necrosis factor therapy in patients with refractory Takayasu arteritis: long-term follow-up. Ann. Rheum. Dis., 2008, 67(11), 1567–1569.

  • 62

    Schmidt, J., Kermani, T. A., Bacani, A. K., et al.: Tumor necrosis factor inhibitors in patients with Takayasu arteritis: experience from a referral center with long-term followup. Arthritis Care Res. (Hoboken), 2012, 64(7), 1079–1083.

  • 63

    Clifford, A., Hoffman, G. S.: Recent advances in the medical management of Takayasu arteritis: an update on use of biologic therapies. Curr. Opin. Rheumatol., 2014, 26(1), 7–15.

  • 64

    Comarmond, C., Plaisier, E., Dahan, K., et al.: Anti TNF-α in refractory Takayasu’s arteritis: cases series and review of the literature. Autoimmun. Rev., 2012, 11(9), 678–684.

  • 65

    Novikov, P. I., Smitienko, I. O., Moiseev, S. V.: Tumor necrosis factor alpha inhibitors in patients with Takayasu’s arteritis refractory to standard immunosuppressive treatment: cases series and review of the literature. Clin. Rheumatol., 2013, 32(12), 1827–1832.

  • 66

    Serra, R., Grande, R., Buffone, G., et al.: Effects of glucocorticoids and tumor necrosis factor-alpha inhibitors on both clinical and molecular parameters in patients with Takayasu arteritis. J. Pharmacol. Pharmacother., 2014, 5(3), 193–196.

  • 67

    Mekinian, A., Comarmond, C., Resche-Rigon, M., et al.: Efficacy of biological-targeted treatments in Takayasu arteritis: multicenter, retrospective study of 49 patients. Circulation, 2015, 132(18), 1693–1700.

  • 68

    Saadoun, D., Garrido, M., Comarmond, C., et al.: Th1 and Th17 cytokines drive inflammation in Takayasu arteritis. Arthritis Rheumatol., 2015, 67(5), 1353–1360.

  • 69

    Park, M. C., Lee, S. W., Park, Y. B., et al.: Serum cytokine profiles and their correlations with disease activity in Takayasu’s arteritis. Rheumatology (Oxford), 2006, 45(5), 545–548.

  • 70

    Nishimoto, N., Nakahara, H., Yoshio-Hoshino, N., et al.: Successful treatment of a patient with Takayasu arteritis using a humanized antiinterleukin-6 receptor antibody. Arthritis Rheum., 2008, 58(4), 1197–1200.

  • 71

    Osman, M., Emery, D., Yacyshyn, E.: Tocilizumab for treating Takayasu’s arteritis and associated stroke: a case series and updated review of the literature. J. Stroke Cerebrovasc. Dis., 2015, 24(6), 1291–1298.

  • 72

    Schiavon, F., Cuffaro, S., Ometto, F., et al.: Takayasu arteritis and NYHA III/IV idiopathic cardiomiopathy: tocilizumab proves effective and safe. Joint Bone Spine, 2014, 81(3), 278–279.

  • 73

    Arita, Y., Nakaoka, Y., Otsuki, M., et al.: Cytokine storm after cessation of tocilizumab in a patient with refractory Takayasu arteritis. Int. J. Cardiol., 2015, 187, 319–321.

  • 74

    Youngstein, T., Peters, J. E., Hamdulay, S. S., et al.: Serial analysis of clinical and imaging indices reveals prolonged efficacy of TNF-α and IL-6 receptor targeted therapies in refractory Takayasu arteritis. Clin. Exp. Rheumatol., 2014, 32(3 Suppl. 82), S11–S18.

  • 75

    Cañas, C. A., Cañas, F., Izquierdo, J. H., et al.: Efficacy and safety of anti-interleukin 6 receptor monoclonal antibody (tocilizumab) in Colombian patients with Takayasu arteritis. J. Clin. Rheumatol., 2014, 20(3), 125–129.

  • 76

    Goel, R., Danda, D., Kumar, S., et al.: Rapid control of disease activity by tocilizumab in 10 ‘difficult-to-treat’ cases of Takayasu arteritis. Int. J. Rheum. Dis., 2013, 16(6), 754–761.

  • 77

    Bredemeier, M., Rocha, C. M., Barbosa, M. V., et al.: One-year clinical and radiological evolution of a patient with refractory Takayasu’s arteritis under treatment with tocilizumab. Clin. Exp. Rheumatol., 2012, 30(1 Suppl. 70), S98– S100.

  • 78

    Xenitidis, T., Horger, M., Zeh, G., et al.: Sustained inflammation of the aortic wall despite tocilizumab treatment in two cases of Takayasu arteritis. Rheumatology (Oxford), 2013, 52(9), 1729–1731.

  • 79

    Mekinian, A., Comarmond, C., Resche-Rigon, M., et al.: Efficacy of biological-targeted treatments in Takayasu arteritis: multicenter retrospective study of 49 patients. Circulation, 2015, 132(18), 1693–1700.

  • 80

    Terao, C.: Revisited HLA and non-HLA genetics of Takayasu arteritis – where are we? J. Hum. Genet., 2016, 61(1), 27–32.

  • 81

    Terao, C., Yoshifuji, H., Nakajima, T., et al.: Ustekinumab as a therapeutic option for Takayasu arteritis: from genetic findings to clinical application. Scand. J. Rheumatol., 2016, 45, 1.

  • 82

    Pountain, G., Hazleman, B., Cawston, T. E.: Circulating levels of IL-1beta, IL-6 and soluble IL-2 receptor in polymyalgia rheumatica and giant cell arteritis and rheumatoid arthritis. Br. J. Rheumatol., 1998, 37(7), 797–798.

  • 83

    Saadoun, D., Grido, M., Comarmond, C., et al.: Th1 and Th17 cytokines drive inflammation in Takayasu arteritis. Arthritis Rheumatol., 2015, 67(5), 1353–1360.

  • 84

    Ly, K. H., Stirnemann, J., Liozon, E., et al.: Interleukin-1 blockade in refractory giant cell arteritis. Joint Bone Spine, 2014, 81(1), 76–78.

  • 85

    Lally, L., Pernis, A., Narula, N., et al.: Increased rho kinase activity in temporal artery biopsies from patients with giant cell arteritis. Rheumatolgy (Oxford), 2015, 54(3), 554–558.

  • 86

    Piggott, K., Deng, J., Warrington, K., et al.: Blocking the NOTCH pathway inhibits vascular inflammation in large-vessel vasculitis. Circulation, 2011, 123(3), 309–318.

All Time Past Year Past 30 Days
Abstract Views 106 101 5
Full Text Views 13 7 1
PDF Downloads 14 7 1